Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified tafasitamab dosing with lenalidomide in relapsed/refractory DLBCL
NCT05222555Phase 2Active, not recruiting
- Sponsor
- Incyte
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of tafasitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Incyte. Started Jul 2022; status: active, not recruiting.
02
Drugs
tafasitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05222555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05222555.